INFOHaem™ MSS FH1536™ Test Result

 

1. Predisposition Risk to Hypercholesterolemia

If you are a healthy person, the test evaluates your subject lifetime risk of developing hypercholesterolemia. The polymorphisms identified from the molecular analysis can be "risk-conferring" or "protective" towards development of hypercholesterolemia. Our bioinformatics solution will establish the subject risk profile based on a proprietary risk scoring algorithms built upon our established research outcome.

 

 

Risk Score and Risk Level

 

Risk Score Risk Level
Less than or equal to -10 Low Risk
-9 to -5 Moderate Risk
More than or equal to -4 High Risk

 

 

 

 

 

High Risk

High Risk indicates that your probability of developing hypercholesterolemia in your lifetime is much higher than that of the general population. An active intervention is advised. Lifestyle change is a must, and frequent biochemical test to examine the blood cholesterol level is highly recommended. Please kindly note the FH diagnosis result to ascertain whether are you a definite FH patient.

 

Moderate Risk

Moderate Risk indicates that you are slightly more likely than the general population to develop hypercholesterolemia in your lifetime. There is no cause for alarm. Adopting a healthy lifestyle and receiving regular medical checkup are sufficient to keep hypercholesterolemia at bay.

 

Mild Risk

Mild Risk indicates that your risk of developing hypercholesterolemia within your lifetime is either the same as, or lower than, the general population. Just keep maintaining a healthy lifestyle, and consult with your physician for the need of regular medical checkup in order to maximize your quality of life.


 

2. Diagnosis of Familial Hypercholesterolemia

If the subject have hypercholesterolemia (established through clinical parameters), the test determines whether your patient harbour the disease causing alleles for FH, thereby diagnoses whether he/she is definite FH or not.

 

FH1536™includes both molecular and clinical examination. Molecular examination involves the scanning of the subject DNA, in search of related polymorphisms inherited from the subject's parents. Clinical examination associates the patient's lifestyle choices, family history and medical history to FH risk. The test scores the clinical examination outcome as well as molecular examination result based on established International Guideline Dutch Lipid Clinic Network Criteria. The combined clinico-molecular analysis thus provides a more thorough and comprehensive assessment.